John Ryan

First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies

Investigational New Drugs · 2013 · 157 citations

Tumor necrosis factor-alpha/cachectin enhances human immunodeficiency virus type 1 replication in primary macrophages

The Journal of Infectious Diseases · 1991 · Last of 5 authors · 156 citations